Literature DB >> 3161772

Induction of rat liver bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin.

Y Adachi, T Nanno, M Yamashita, S Ueshima, T Yamamoto.   

Abstract

After oral administration of rifampicin and 25-desacetylrifampicin, which is a major metabolite of rifampicin in man but not in rat, to male Wister rats for 7 days, hepatic microsomal cytochrome P450, cytochrome b5, and activities of aniline hydroxylase, aminopyrine demethylase, bilirubin-conjugating enzymes and supernatant glutathione S-transferase were measured. Rifampicin induced bilirubin UDP-glucuronyltransferase, bilirubin UDP-glucosyltransferase, bilirubin UDP-xylosyltransferase and glutathione S-transferase activities, but did not induce mixed function oxidase activities. No inductive effect of desacetylrifampicin on any enzymes was observed. Serum bilirubin increased till the third day, and decreased after 7 days of rifampicin treatment. Plasma clearances of indocyanine green and sulfobromophthalein showed a marked delay after 1 day and 7 days of rifampicin treatment. Induction of bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin in rats was different from that in humans, in which selective induction of mixed function oxidase is reported to occur. This species difference does not seem to be derived from the species difference of rifampicin metabolism, because no effect of desacetylrifampicin was observed. These results suggested that in rats rifampicin directly inhibits the hepatic excretion of bilirubin, whereas it enhances bilirubin conjugation due to enzyme induction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161772     DOI: 10.1007/bf02776672

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  18 in total

1.  Influence of drugs and chemical upon hepatic enzymes and proteins-I. Structure-activity relationship between various barbiturates and microsomal enzyme induction in rat liver.

Authors:  Y Adachi; T Yamamoto
Journal:  Biochem Pharmacol       Date:  1976-03-15       Impact factor: 5.858

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

4.  Biochemical and pharmacological changes in the rat following chronic administration of morphine nalorphine and normorphine.

Authors:  J COCHIN; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1959-02       Impact factor: 4.030

5.  [The determination of bilirubin as azobilirubin in plasma and serum with the Greiner electronic selective analyzer GSA II (author's transl)].

Authors:  H Küffer; R Richterich; E Peheim; J P Colombo
Journal:  Z Klin Chem Klin Biochem       Date:  1974-06

6.  Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications.

Authors:  S Kenwright; A J Levi
Journal:  Lancet       Date:  1973-12-22       Impact factor: 79.321

7.  Evidence for biochemically different types of vesicles in the hepatic microsomal fraction.

Authors:  Y Imai; A Ito; R Sato
Journal:  J Biochem       Date:  1966-10       Impact factor: 3.387

8.  Enzymic transfer of glucose and xylose from uridine diphosphate glucose and uridine diphosphate xylose to bilirubin by untreated and digitonin-activated preparations from rat liver.

Authors:  J Fevery; P Leroy; K P Heirwegh
Journal:  Biochem J       Date:  1972-09       Impact factor: 3.857

9.  Assay and properties of dititonin-activated bilirubin uridine diphosphate glucuronyltransferase from rat liver.

Authors:  K P Heirwegh; M Van de Vijver; J Fevery
Journal:  Biochem J       Date:  1972-09       Impact factor: 3.857

10.  Changes in cortisol metabolism following rifampicin therapy.

Authors:  O M Edwards; R J Courtenay-Evans; J M Galley; J Hunter; A D Tait
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

View more
  7 in total

1.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

2.  Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients.

Authors:  K D Gallicano; J Sahai; V K Shukla; I Seguin; A Pakuts; D Kwok; B C Foster; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 3.  CYP induction-mediated drug interactions: in vitro assessment and clinical implications.

Authors:  Jiunn H Lin
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

4.  Role of N-acetylcysteine in rifampicin-induced hepatic injury of young rats.

Authors:  S-V Rana; S Attri; K Vaiphei; R Pal; A Attri; K Singh
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

5.  Influence of rifampicin on the toxicity and the analgesic effect of acetaminophen.

Authors:  S Dimova; T Stoytchev
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

6.  Oleanolic Acid and Ursolic Acid Induce UGT1A1 Expression in HepG2 Cells by Activating PXR Rather Than CAR.

Authors:  Na Yao; Caiwen Zeng; Tao Zhan; Fang He; Mingyi Liu; Fanglan Liu; Hong Zhang; Yuqing Xiong; Chunhua Xia
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

Review 7.  Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

Authors:  M Strolin Benedetti; P Dostert
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.